Literature DB >> 19324841

Clinical and molecular evaluation of probands and family members with familial exudative vitreoretinopathy.

F Nienke Boonstra1, C Erik van Nouhuys, José Schuil, Ilse J de Wijs, Kim P van der Donk, Kostas Nikopoulos, Arijit Mukhopadhyay, Hans Scheffer, Mauk A D Tilanus, Frans P M Cremers, Lies H Hoefsloot.   

Abstract

PURPOSE: To describe the ophthalmic characteristics and to identify the molecular cause of FEVR in a cohort of Dutch probands and their family members.
METHODS: Twenty families with familial exudative vitreoretinopathy (FEVR) comprising 83 affected and nonaffected individuals were studied. Based on the presence of an avascular zone, the clinical diagnosis was made and biometric data of the posterior pole of 57 patients and family members were obtained by the analysis of fundus photographs and compared with the data of 40 controls. The FZD4, LRP5, and NDP genes were screened for mutations in one affected individual per family. The segregation of the gene variants was studied in the corresponding families.
RESULTS: Forty of 83 individuals showed an avascular zone, the most evident clinical sign of FEVR, five showed major signs of FEVR, and 38 persons were not clinically affected. Compared with the control subjects the patients with FEVR had a significantly larger disc-to-macula distance and a significantly smaller optic disc. In 8 of 20 families, a FZD4 mutation was identified, in 2 a mutation in the LRP5 gene, and in 2 a mutation in the NDP gene. Three known and five novel mutations were identified. Nonpenetrance was observed in 26% of the mutation carriers.
CONCLUSIONS: Significant anatomic differences were identified between the eyes of patients with FEVR with an avascular zone, when compared with those of the control subjects. In patients with an avascular zone, the optic disc was smaller and the disc-to-macula distance larger than in the control subjects. In 60% of the probands, mutations were identified in one of the three known FEVR genes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19324841     DOI: 10.1167/iovs.08-3320

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  24 in total

1.  Familial exudative vitreoretinopathy with an anterior segment vasoproliferative mass.

Authors:  Maria Teresa Sandinha; Laura Crawley; Caroline Thaung; Lyndon Da Cruz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-01       Impact factor: 3.117

2.  The characteristics of digenic familial exudative vitreoretinopathy.

Authors:  Yian Li; Jie Peng; Jiakai Li; Qi Zhang; Jing Li; Xiang Zhang; Ping Fei; Kaiqin She; Peiquan Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-10       Impact factor: 3.117

3.  Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy.

Authors:  Konstantinos Nikopoulos; Christian Gilissen; Alexander Hoischen; C Erik van Nouhuys; F Nienke Boonstra; Ellen A W Blokland; Peer Arts; Nienke Wieskamp; Tim M Strom; Carmen Ayuso; Mauk A D Tilanus; Sanne Bouwhuis; Arijit Mukhopadhyay; Hans Scheffer; Lies H Hoefsloot; Joris A Veltman; Frans P M Cremers; Rob W J Collin
Journal:  Am J Hum Genet       Date:  2010-02-12       Impact factor: 11.025

4.  Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy.

Authors:  James A Poulter; Manir Ali; David F Gilmour; Aine Rice; Hiroyuki Kondo; Kenshi Hayashi; David A Mackey; Lisa S Kearns; Jonathan B Ruddle; Jamie E Craig; Eric A Pierce; Louise M Downey; Moin D Mohamed; Alexander F Markham; Chris F Inglehearn; Carmel Toomes
Journal:  Am J Hum Genet       Date:  2010-02-12       Impact factor: 11.025

5.  Next-generation sequencing and novel variant determination in a cohort of 92 familial exudative vitreoretinopathy patients.

Authors:  Jason Salvo; Vera Lyubasyuk; Mingchu Xu; Hui Wang; Feng Wang; Duy Nguyen; Keqing Wang; Hongrong Luo; Cindy Wen; Catherine Shi; Danni Lin; Kang Zhang; Rui Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-02-24       Impact factor: 4.799

6.  ZNF408 is mutated in familial exudative vitreoretinopathy and is crucial for the development of zebrafish retinal vasculature.

Authors:  Rob W J Collin; Konstantinos Nikopoulos; Margo Dona; Christian Gilissen; Alexander Hoischen; F Nienke Boonstra; James A Poulter; Hiroyuki Kondo; Wolfgang Berger; Carmel Toomes; Tomoko Tahira; Lucas R Mohn; Ellen A Blokland; Lisette Hetterschijt; Manir Ali; Johanne M Groothuismink; Lonneke Duijkers; Chris F Inglehearn; Lea Sollfrank; Tim M Strom; Eiichi Uchio; C Erik van Nouhuys; Hannie Kremer; Joris A Veltman; Erwin van Wijk; Frans P M Cremers
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

7.  LONGITUDINAL CHANGES IN THE OPTIC NERVE HEAD AND RETINA OVER TIME IN VERY YOUNG CHILDREN WITH FAMILIAL EXUDATIVE VITREORETINOPATHY.

Authors:  Jonghyun Lee; Mays A El-Dairi; Du Tran-Viet; Shwetha Mangalesh; Alexandria Dandridge; Kim Jiramongkolchai; Christian Viehland; Cynthia A Toth
Journal:  Retina       Date:  2019-01       Impact factor: 4.256

8.  Novel TSPAN12 mutations in patients with familial exudative vitreoretinopathy and their associated phenotypes.

Authors:  Huiqin Yang; Xueshan Xiao; Shiqiang Li; Guiying Mai; Qingjiong Zhang
Journal:  Mol Vis       Date:  2011-04-29       Impact factor: 2.367

9.  Next generation sequencing identifies mutations in Atonal homolog 7 (ATOH7) in families with global eye developmental defects.

Authors:  Kamron Khan; Clare V Logan; Martin McKibbin; Eamonn Sheridan; Nursel H Elçioglu; Ozlem Yenice; David A Parry; Narcis Fernandez-Fuentes; Zakia I A Abdelhamed; Ahmed Al-Maskari; James A Poulter; Moin D Mohamed; Ian M Carr; Joanne E Morgan; Hussain Jafri; Yasmin Raashid; Graham R Taylor; Colin A Johnson; Chris F Inglehearn; Carmel Toomes; Manir Ali
Journal:  Hum Mol Genet       Date:  2011-11-07       Impact factor: 6.150

10.  Identification of FZD4 and LRP5 mutations in 11 of 49 families with familial exudative vitreoretinopathy.

Authors:  Huiqin Yang; Shiqiang Li; Xueshan Xiao; Panfeng Wang; Xiangming Guo; Qingjiong Zhang
Journal:  Mol Vis       Date:  2012-10-04       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.